NASDAQ$PSNL

Personalis Inc · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

Personalis reported Q1 2025, revenue of $20.6M, a net loss of $15.8M, diluted EPS of ($0.18).

For Q1 2025, Personalis reported revenue of $20.6M, a net loss of $15.8M, diluted EPS was ($0.18). The filing highlights segment performance, liquidity, and management commentary on the period.

  • Revenue $20.6M.
  • Net loss $15.8M.
  • Diluted EPS ($0.18).

Headline financials

Total Revenue

$20.6M

Previous: $19.5M+5.5%
EPS (adj)

-$0.18

Previous: -$0.26+30.8%
Total clinical tests delivered

2.2K

No prior period
Gross margin

35.0%

Previous: 28.1%+24.6%
Capital Expenditures

-$2.51M

Previous: -$104K-2314.4%
Net Income

-$15.8M

Previous: -$13M-21.5%
Operating Income

-$17.7M

Previous: -$18.9M+6.3%
Gross Profit

$7.21M

Previous: $5.49M+31.2%

Revenue & EPS history

Personalis · Revenue · Quarterly

$20.6M

Q1 2025+5.5%vs Q1 2024
Beat estimate in 13 of 14 quarters(93%)
ActualEstimate

Revenue by segment

Personalis · $18.2M total across 4 segments · Q3 2023

  • Pharma tests and services
    $8M
  • Enterprise sales
    $7.81M
  • Population sequencing
    $2.4M
  • Other
    $38K

Forward guidance

Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.

Tailwinds

  • Headline results and segment trends anchor the quarter.
  • Liquidity and balance-sheet capacity support operations.
  • Strategic initiatives outlined in MD&A.

Headwinds

  • Macro, rates, or input costs may pressure margins.
  • One-time items affect year-over-year comparability.
  • Execution risk on growth or restructuring plans.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+1.0%

Avg return

Earnings day

+1.5%

Avg return

5 days after

+1.5%

Avg return

30 days after

59%

16 / 27 earnings

Positive

+19.9%

Q1 2025

Best reaction

-23.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.2%-0.7%+76.6%
Q4 2025+0.6%-1.1%-29.8%
Q3 2025-12.3%-1.1%+9.5%
Q1 2025+19.9%+27.5%+30.3%
Q4 2024-2.4%+5.9%-14.6%
Q3 2024-23.4%-12.8%-26.4%
Q2 2024+7.2%+34.7%+67.8%
Q1 2024+4.4%-2.5%-14.6%
Q4 2023+3.3%+16.0%-0.7%
Q3 2023+10.4%-3.8%+39.6%
Q2 2023+4.7%+7.9%-17.9%
Q1 2023+4.5%+3.2%-6.4%
Q4 2022-7.2%-5.3%-18.2%
Q3 2022-1.5%-15.3%+4.7%
Q2 2022+10.6%+11.1%-21.4%
Q1 2022-7.2%-24.8%-34.1%
Q4 2021+12.2%+11.0%-14.4%
Q3 2021+2.6%-5.4%-38.9%
Q2 2021+10.2%+4.1%+12.4%
Q1 2021-0.6%-9.9%-4.3%
Q4 2020-11.1%-10.8%-36.3%
Q3 2020+0.1%-0.3%+13.6%
Q2 2020-2.4%-3.7%-4.7%
Q1 2020+4.6%+7.2%+27.6%
Q4 2019+17.5%+27.5%+52.8%
Q3 2019+0.2%-12.7%+0.3%
Q2 2019-15.6%-6.2%-11.6%
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro